drugset / Trial / NCT05291845

Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts

NCT05291845

Phase 2 Recruiting 162 enrolled Zagazig University
RandomizedFactorialOpen-labelTreatment

Summary

To follow up the efficacy and safety of Candida antigen, bivalent HPV vaccine in treatment of common warts either mono or combined intralesional therapy

Timeline

Start
2022-04-03
Primary completion
2025-10-03
Completion
2025-12-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Candida antigen vaccine Vaccine Other
Subject Cervarix Vaccine Other